To effectively enhance the therapy of ovarian cancer, an impressive delivery system was designed, which includes a PPI dendrimer, a synthetic analog of LHRH peptide, paclitaxel, and siRNA molecules targeted to CD44 mRNA, together to be a specific CD44+ ovarian cancer cell death inducer. Here, CD44 is linked to ovarian carcinoma.